Brokerages Expect Amedisys Inc (AMED) Will Announce Earnings of $0.79 Per Share

Analysts expect Amedisys Inc (NASDAQ:AMED) to report earnings of $0.79 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Amedisys’ earnings. The highest EPS estimate is $0.93 and the lowest is $0.72. Amedisys posted earnings per share of $0.56 in the same quarter last year, which indicates a positive year-over-year growth rate of 41.1%. The firm is scheduled to report its next earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Amedisys will report full-year earnings of $3.42 per share for the current fiscal year, with EPS estimates ranging from $3.37 to $3.60. For the next fiscal year, analysts anticipate that the firm will post earnings of $3.94 per share, with EPS estimates ranging from $3.78 to $4.20. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover Amedisys.

Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, July 31st. The health services provider reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.22. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. The business had revenue of $411.60 million during the quarter, compared to analysts’ expectations of $403.62 million. During the same period in the prior year, the business earned $0.62 EPS.

A number of research firms recently issued reports on AMED. Robert W. Baird increased their target price on Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday. SunTrust Banks increased their target price on Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald increased their target price on Amedisys from $117.00 to $125.00 and gave the stock a “neutral” rating in a research note on Thursday. Bank of America set a $139.00 target price on Amedisys and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Finally, Canaccord Genuity began coverage on Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $95.38.

NASDAQ AMED traded down $4.21 during trading hours on Monday, reaching $109.28. 640,680 shares of the company’s stock were exchanged, compared to its average volume of 312,146. Amedisys has a one year low of $45.60 and a one year high of $127.38. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.21 and a current ratio of 1.21. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 49.45, a PEG ratio of 1.89 and a beta of 1.00.

In other Amedisys news, insider David B. Pearce sold 398 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total transaction of $48,440.58. Following the completion of the transaction, the insider now owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in AMED. SG Americas Securities LLC acquired a new position in Amedisys during the 1st quarter worth approximately $123,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Amedisys in the 2nd quarter valued at approximately $149,000. Mount Yale Investment Advisors LLC acquired a new stake in shares of Amedisys in the 1st quarter valued at approximately $151,000. Moneta Group Investment Advisors LLC acquired a new stake in shares of Amedisys in the 2nd quarter valued at approximately $181,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Amedisys by 1,086.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after buying an additional 2,172 shares during the last quarter. 93.31% of the stock is owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Article: What is a Stop Order?

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply